麻保沙星对实验性猪传染性胸膜肺炎的药效学研究

Efficacy of Marbofloxacin against Experimentally Induced Actinobacillus pleuropneumoniae in Swine

采用二倍稀释法测定了麻保沙星等对猪胸膜肺炎放线杆菌的体外抑菌作用,然后对人工感染胸膜肺炎放线杆菌的猪进行临床治疗试验。猪人工发病4 h后,分别以1.25、2.5、5 mg/kg体重的剂量肌注给药麻保沙星(每组10头),1 d 1次,连续4 d。结果表明:麻保沙星对胸膜肺炎放线杆菌的最小抑菌浓度为0.01μg/mL;对猪传染性胸膜肺炎,麻保沙星(2.5、5 mg/kg)有显著疗效,治愈率分别为80%及90%。

The efficacy of marbofloxacin against experimentally induced Actinobacillus pleuropneumoniae in swine was tested to provide the experimental basis for its broad clinical application. 4 h later after the artificial inoculation infection, the swine were treated with the dosage of 1.25, 2.5, 5 mg/kg body weight once daily by intramuscular administration for 4 successive days. The results showed that in vitro mini- real inhibitory concentration （ MIC ） of marbofloxacin against Actinobacillus pleuropneumoniae was 0.01 μg/mL. The therapeutic trials showed that marbofloxaein（2.5, 5 mg/kg） was efficacious in the control of A. pleuropneumoniae infection in swine, and the curative rates were 80 % and 90 %, respectively.